蛋白酶体抑制剂-话题@MedSci

#蛋白酶体抑制剂#

8篇内容 | 900人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2187926, encodeId=8772218e9266b, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=5b8088e6609' target=_blank style='color:#2F92EE;'>#蛋白酶体抑制剂#</a> <a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, objectTitle=Hematology：接受蛋白酶体抑制剂治疗的功能性高风险多发性骨髓瘤患者血清指标的回顾性研究, objectType=article, longId=813678, objectId=93c48136e85a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221120/1669014235000_4754896.webp, objectUrl=/article/show_article.do?id=93c48136e85a, replyNumber=0, likeNumber=22, createdTime=2024-02-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=93c48136e85a, moduleTitle=Hematology：接受蛋白酶体抑制剂治疗的功能性高风险多发性骨髓瘤患者血清指标的回顾性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93c48136e85a)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2185492, encodeId=48a82185492cd, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a> <a href='/topic/show?id=5b8088e6609' target=_blank style='color:#2F92EE;'>#蛋白酶体抑制剂#</a>, objectTitle=Pancreatology:蛋白酶抑制剂不能预防胰腺切除术后急性胰腺炎的发生, objectType=article, longId=806507, objectId=c1fb80650e2d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301009/1696890850643_4754896.jpeg, objectUrl=/article/show_article.do?id=c1fb80650e2d, replyNumber=0, likeNumber=21, createdTime=2024-02-02, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=加利福尼亚, moduleDTOList=[ModuleDTO(moduleId=c1fb80650e2d, moduleTitle=Pancreatology:蛋白酶抑制剂不能预防胰腺切除术后急性胰腺炎的发生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1fb80650e2d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2121876, encodeId=fc6321218e6f5, content=在临床前骨髓瘤模型中，<a href='/topic/show?id=368d105e1469' target=_blank style='color:#2F92EE;'>#iberdomide#</a>已显示出与<a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a>、<a href='/topic/show?id=5b8088e6609' target=_blank style='color:#2F92EE;'>#蛋白酶体抑制剂#</a>和<a href='/topic/show?id=229b105e153a' target=_blank style='color:#2F92EE;'>#CD38单克隆抗体#</a>的协同作用，治疗<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>，同样也显示出对<a href='/topic/show?id=257ae692755' target=_blank style='color:#2F92EE;'>#系统性红斑狼疮#</a>的治疗活性, objectTitle=Lancet Haematol：Iberdomide联合地塞米松治疗复发/难治性多发性骨髓瘤, objectType=article, longId=741920, objectId=512be41920f4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202201007/1665126448581_2110107.JPG, objectUrl=/article/show_article.do?id=512be41920f4, replyNumber=0, likeNumber=103, createdTime=2023-03-26, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=512be41920f4, moduleTitle=Lancet Haematol：Iberdomide联合地塞米松治疗复发/难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=512be41920f4)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1650555, encodeId=34091650555ff, content=<a href='/topic/show?id=5b8088e6609' target=_blank style='color:#2F92EE;'>#蛋白酶体抑制剂#</a>, objectTitle=Front Immunol：蛋白酶体抑制剂硼替佐米治疗重症系统性红斑狼疮疗效和安全性的临床经验, objectType=article, longId=219213, objectId=3deb219213a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3deb219213a1, replyNumber=0, likeNumber=43, createdTime=2022-07-03, rootId=0, userName=changjitao2017, userId=379e24021255, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3deb219213a1, moduleTitle=Front Immunol：蛋白酶体抑制剂硼替佐米治疗重症系统性红斑狼疮疗效和安全性的临床经验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3deb219213a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650554, encodeId=0140165055499, content=<a href='/topic/show?id=5b8088e6609' target=_blank style='color:#2F92EE;'>#蛋白酶体抑制剂#</a>, objectTitle=Blood：MIF是克服多发性骨髓瘤对蛋白酶体抑制剂耐药的生物标志物和靶点, objectType=article, longId=196922, objectId=a78819692202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a78819692202, replyNumber=0, likeNumber=0, createdTime=2020-10-25, rootId=0, userName=changjitao2017, userId=379e24021255, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a78819692202, moduleTitle=Blood：MIF是克服多发性骨髓瘤对蛋白酶体抑制剂耐药的生物标志物和靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a78819692202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650552, encodeId=559b165055242, content=<a href='/topic/show?id=5b8088e6609' target=_blank style='color:#2F92EE;'>#蛋白酶体抑制剂#</a>, objectTitle=Blood：14-3-3蛋白调节MM对蛋白酶体抑制剂的敏感性, objectType=article, longId=190569, objectId=b40d1905696a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b40d1905696a, replyNumber=0, likeNumber=48, createdTime=2020-12-19, rootId=0, userName=changjitao2017, userId=379e24021255, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b40d1905696a, moduleTitle=Blood：14-3-3蛋白调节MM对蛋白酶体抑制剂的敏感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b40d1905696a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650553, encodeId=ac51165055383, content=<a href='/topic/show?id=5b8088e6609' target=_blank style='color:#2F92EE;'>#蛋白酶体抑制剂#</a>, objectTitle=Circulation：免疫蛋白酶体抑制剂可减轻自体免疫相关性心肌炎的心脏特异性免疫反应, objectType=article, longId=195871, objectId=ec211958e16b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec211958e16b, replyNumber=0, likeNumber=41, createdTime=2020-09-20, rootId=0, userName=changjitao2017, userId=379e24021255, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec211958e16b, moduleTitle=Circulation：免疫蛋白酶体抑制剂可减轻自体免疫相关性心肌炎的心脏特异性免疫反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec211958e16b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650551, encodeId=959216505518e, content=<a href='/topic/show?id=5b8088e6609' target=_blank style='color:#2F92EE;'>#蛋白酶体抑制剂#</a>, objectTitle=Blood：IDH2抑制可增强蛋白酶体抑制剂的抗癌效果, objectType=article, longId=154181, objectId=1ed4154181b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ed4154181b8, replyNumber=0, likeNumber=44, createdTime=2019-10-20, rootId=0, userName=changjitao2017, userId=379e24021255, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ed4154181b8, moduleTitle=Blood：IDH2抑制可增强蛋白酶体抑制剂的抗癌效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ed4154181b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650550, encodeId=9ae51650550e1, content=<a href='/topic/show?id=5b8088e6609' target=_blank style='color:#2F92EE;'>#蛋白酶体抑制剂#</a>, objectTitle=EMBO Molecular Medicine:蛋白酶体抑制剂可抑制严重心肌炎, objectType=article, longId=130795, objectId=28e3130e958a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28e3130e958a, replyNumber=0, likeNumber=35, createdTime=2018-10-26, rootId=0, userName=changjitao2017, userId=379e24021255, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28e3130e958a, moduleTitle=EMBO Molecular Medicine:蛋白酶体抑制剂可抑制严重心肌炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28e3130e958a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650549, encodeId=7c0b1650549aa, content=<a href='/topic/show?id=5b8088e6609' target=_blank style='color:#2F92EE;'>#蛋白酶体抑制剂#</a>, objectTitle=Lancet Oncology：多发性骨髓瘤患者的福音——口服型蛋白酶体抑制剂Ixazomib, objectType=article, longId=42889, objectId=dba242889af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dba242889af, replyNumber=0, likeNumber=40, createdTime=2015-07-16, rootId=0, userName=changjitao2017, userId=379e24021255, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dba242889af, moduleTitle=Lancet Oncology：多发性骨髓瘤患者的福音——口服型蛋白酶体抑制剂Ixazomib, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dba242889af)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

蛋白酶体抑制剂

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #蛋白酶体抑制剂# #回顾性研究#

Hematology：接受蛋白酶体抑制剂治疗的功能性高风险多发性骨髓瘤患者血清指标的回顾性研究

2024-02-18发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#胰腺癌# #蛋白酶体抑制剂#

Pancreatology:蛋白酶抑制剂不能预防胰腺切除术后急性胰腺炎的发生

2024-02-02发表于加利福尼亚

(审核中...)

前往app查看评论内容

在临床前骨髓瘤模型中，#iberdomide#已显示出与#地塞米松#、#蛋白酶体抑制剂#和#CD38单克隆抗体#的协同作用，治疗#多发性骨髓瘤#，同样也显示出对#系统性红斑狼疮#的治疗活性

Lancet Haematol：Iberdomide联合地塞米松治疗复发/难治性多发性骨髓瘤

2023-03-26发表于上海

changjitao2017 (审核中...)

前往app查看评论内容

#蛋白酶体抑制剂#

Front Immunol：蛋白酶体抑制剂硼替佐米治疗重症系统性红斑狼疮疗效和安全性的临床经验

2022-07-03

changjitao2017 (审核中...)

前往app查看评论内容

#蛋白酶体抑制剂#

Blood：MIF是克服多发性骨髓瘤对蛋白酶体抑制剂耐药的生物标志物和靶点

2020-10-25

changjitao2017 (审核中...)

前往app查看评论内容

#蛋白酶体抑制剂#

Blood：14-3-3蛋白调节MM对蛋白酶体抑制剂的敏感性

2020-12-19

changjitao2017 (审核中...)

前往app查看评论内容

#蛋白酶体抑制剂#

Circulation：免疫蛋白酶体抑制剂可减轻自体免疫相关性心肌炎的心脏特异性免疫反应

2020-09-20

changjitao2017 (审核中...)

前往app查看评论内容

#蛋白酶体抑制剂#

Blood：IDH2抑制可增强蛋白酶体抑制剂的抗癌效果

2019-10-20

changjitao2017 (审核中...)

前往app查看评论内容

#蛋白酶体抑制剂#

EMBO Molecular Medicine:蛋白酶体抑制剂可抑制严重心肌炎

2018-10-26

changjitao2017 (审核中...)

前往app查看评论内容

#蛋白酶体抑制剂#

Lancet Oncology：多发性骨髓瘤患者的福音——口服型蛋白酶体抑制剂Ixazomib

2015-07-16

科室
- - 订阅+
  - 更多科室
工具
服务